The largest study to date that analyzed patterns of GLP‐1 RA use in breast cancer survival was a retrospective study that analyzed roughly 1022 patients with non‐metastatic (DCIS or invasive stage I‐III) at MD Anderson Cancer Center who received at least 3 months of semaglutide and tirzepatide. Here, GLP1R is linked to breast carcinoma.